Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Alx Oncology Holdings (ALXO) Research & Development (2019 - 2023)

Alx Oncology Holdings' Research & Development history spans 5 years, with the latest figure at $41.8 million for Q4 2023.

  • For Q4 2023, Research & Development rose 65.83% year-over-year to $41.8 million; the TTM value through Dec 2023 reached $141.8 million, up 44.1%, while the annual FY2025 figure was $77.0 million, 33.84% down from the prior year.
  • Research & Development for Q4 2023 was $41.8 million at Alx Oncology Holdings, down from $45.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $45.8 million in Q3 2023 and bottomed at $2.2 million in Q3 2019.
  • The 5-year median for Research & Development is $17.6 million (2021), against an average of $18.8 million.
  • The largest annual shift saw Research & Development surged 241.85% in 2021 before it rose 10.22% in 2023.
  • A 5-year view of Research & Development shows it stood at $6.7 million in 2019, then skyrocketed by 80.28% to $12.1 million in 2020, then soared by 72.08% to $20.9 million in 2021, then rose by 20.59% to $25.2 million in 2022, then skyrocketed by 65.83% to $41.8 million in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Research & Development are $41.8 million (Q4 2023), $45.8 million (Q3 2023), and $29.5 million (Q2 2023).